Of the primary breast cancers to residual lesions, HER2-negative converted to HER2-positive in 5 (1.7%) cases, and HER2-positive converted to HER2-negative in 10 (3.4%) cases. This evidence concerns the gene ERBB2 and breast carcinoma.